GPRC5D and plasma cell myeloma: Therapies targeting GPRC5D focus on monoclonal antibodies and CAR‐T cells, effectively targeting and eliminating myeloma cells expressing this receptor.[17,18] However, despite the significant efficacy demonstrated by immunotherapy strategies such as CAR‐T therapy, their high cost, complex production processes, and potential toxicities, such as cytokine release syndrome, limit their widespread accessibility.